

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and
Trademark Office on the date shown below to
Facsimile Telephone Number (703) 872-9306

Donna J. Hittle

Signature

5/3/05

Date

**RECEIVED
CENTRAL FAX CENTER**

MAY 03 2005

Attorney Docket No.GP50029-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Agarwal, et al 27 April 2005
Serial No.: 10/687,268 Group Art Unit: 1647
Filed: 05 May 2003 Examiner: J. Lyles
For: NOVEL COMPOUNDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

REPLY TO REQUIREMENT TO RESTRICT UNDER 35 U.S.C. § 121

Sir:

This paper is in response to the Restriction Requirement dated April 6, 2005, setting forth a thirty (30) day shortened statutory period for reply. Claims 1-25 are pending in the application. Claims 1-25 are subject to restriction and/or election requirement. As this response is timely filed within the shortened statutory period for response of thirty (30) days, no fee is required. Please charge any additional fees relating to this paper to Deposit Account No. 19-2570.

Restriction is required under 35 U.S.C 121.

Group I. Claims 1-3 and 14-15, drawn to an isolated polypeptide and a pharmaceutical composition, classified in class 530, subclass 350 and class 514, subclass 2.

Group II. Claims 4-3, and 16-19, drawn to an isolated polynucleotide, a pharmaceutical composition comprising of polynucleotide, an expression

Application No.: 10/687,268
Group Art Unit: 1647

2

vector, recombinant host cells, a method for producing the host cells, and a method for producing a polypeptide, classified in class 536, subclass 23.5, class 435, subclasses 325 and 69.1.

- Group III Claims 20-21, drawn to a method for treating a wound comprising administering a pharmaceutical composition comprising a polypeptide, classified in class 514, subclass 2.
- Group IV Claims 22-25, drawn to a method for treating a wound administering a pharmaceutical composition comprising a polynucleotide, classified in class 514, subclass 44.

In response to the Restriction Requirement, Applicants elect Examiner's Group I, claims 1-3 and 14-15, with traverse. Furthermore from Group 1, Applicants elects a polypeptide of SEQ ID NO:35.

Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims to non-elected inventions, the claims as originally filed, and any other claims supported by the specification.

Respectfully submitted,



William T. Han
Attorney for Applicant
Registration No. 34,344

GlaxoSmithKline Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5263
Facsimile (610) 270-5090
N:\Han\APPS\GP50029-1\Restriction Requirement.doc